Physician profile
David Robertson
NPI 1265647945
$61,618.65
in general payments reported to CMS, 2019-2025
41 companies · $35K in 2025
The $35K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,661 · 2021: $2,600 · 2022: $3,521 · 2023: $4,063 · 2024: $3,535 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $11K · Travel and Lodging: $2,828 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,487.50 |
| Food and Beverage | $11,165.10 |
| Travel and Lodging | $2,828.24 |
| Education | $231.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34,058.26 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $10,145.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,788.59 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Pfizer INC. | $1,868.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,505.21 | 2019-2025 | |
| Optinose US, INC. | $1,152.08 | 2019-2025 | |
| Csl Behring | $1,128.30 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $1,103.59 | 2019-2025 | |
| Genentech USA, INC. | $920.88 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $873.24 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Amgen INC. | $728.54 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $582.73 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $463.38 | 2019-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.98 | 2019-2023 | Spiriva Respimat |
| Abbvie INC. | $340.80 | 2022-2023 | Rinvoq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $251.29 | 2022-2025 | Opzelura |
| Octapharma USA, INC. | $237.12 | 2019-2020 | |
| Leo Pharma INC. | $224.41 | 2022-2024 | Adbry |
| Lilly USA, LLC | $169.64 | 2024-2025 | Ebglyss |
| Teva Pharmaceuticals USA, INC. | $164.84 | 2019-2021 | |
| Blueprint Medicines Corporation | $162.21 | 2023-2024 | Ayvakit |
| Kaleo, INC. | $151.56 | 2021-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $151.53 | 2021-2022 | |
| Shire North American Group INC | $137.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $132.38 | 2020-2024 | |
| Gc Biopharma USA, INC. | $115.49 | 2024-2025 | Alyglo, Alyglo |
| Covis Pharma Gmbh | $93.45 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $75.65 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $73.94 | 2022-2023 | Orladeyo |
| Alk-Abello, INC | $62.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.26 | 2019-2023 | |
| Horizon Therapeutics Plc | $46.27 | 2022-2023 | Actimmune |
| Greer Laboratories, INC. | $44.92 | 2024-2025 | Palforzia |
| Galderma Laboratories, L.P. | $40.89 | 2024-2025 | Nemluvio |
| Verona Pharma, INC. | $36.39 | 2025 | Ohtuvayre |
| Phadia US INC. | $31.46 | 2024-2025 | Immunocap |
| Azurity Pharmaceuticals, INC. | $30.83 | 2025 | Alvesco |
| Organon LLC | $30.58 | 2025 | |
| Cycle Pharmaceuticals INC | $24.61 | 2024 | Sajazir |
| Bio Products Laboratory USA, INC. | $20.12 | 2022 | |
| Invivyd INC | $17.00 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.